Aurobindo Pharma Limited (BOM:524804)
India
· Delayed Price · Currency is INR | Market Cap | 647.68B |
| Revenue (ttm) | 309.22B |
| Net Income (ttm) | 34.91B |
| Shares Out | n/a |
| EPS (ttm) | 59.81 |
| PE Ratio | 18.55 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,011 |
| Average Volume | 21,578 |
| Open | 1,121.30 |
| Previous Close | 1,120.85 |
| Day's Range | 1,097.75 - 1,125.55 |
| 52-Week Range | 985.00 - 1,592.55 |
| Beta | n/a |
| RSI | 40.18 |
| Earnings Date | Feb 7, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi... [Read more]
Financial Performance
In 2023, Aurobindo Pharma's revenue was 290.02 billion, an increase of 16.68% compared to the previous year's 248.55 billion. Earnings were 31.73 billion, an increase of 64.62%.
Financial StatementsNews
Pharma stocks drop up to 7% after Trump announces 25% tariff on imports
Shares of Indian pharmaceutical companies fell sharply on Wednesday after former U.S. President Donald Trump announced plans to impose a 25% tariff on imported pharmaceuticals, aiming to boost domesti...
Aurobindo shares fall 7% as US FDA issues 5 observations on pre-approval inspection for Andhra unit
Shares of Aurobindo Pharma fell by 7% to ₹1,098.10 after the company disclosed that the U.S. Food and Drug Administration (US FDA) had issued five observations for its step-down subsidiary Eugia Steri...
US FDA completes action with 5 observations for Aurobindo Pharma’s Eugia Steriles facility
Aurobindo Pharma’s Eugia Steriles Facility Completes US FDA Pre-Approval Inspection with Five Observations Aurobindo Pharma Limited announced that its step-down subsidiary, Eugia Steriles Private Limi...
Pharma stocks rally: Aurobindo Pharma up 4.05%, Lupin jumps 3.81%, Biocon gains 2.80% at market open
Pharmaceutical stocks opened on a strong note on Tuesday, with several leading companies witnessing sharp gains. Aurobindo Pharma surged 4.05% to ₹1,190.95, leading the sectoral rally and attracting s...
Aurobindo Pharma’s API Unit 2 in Telangana receives VAI classification from US FDA, EIR issued
Aurobindo Pharma announced that its API manufacturing Unit 2, located in Gaddapotharam Village, Telangana, has been classified as “Voluntary Action Indicated” (VAI) by the US Food and Drug Administrat...
Aurobindo Pharma subsidiary’s facility receives EIR from US FDA with VAI classification
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) has completed its inspection of Unit-2, an API manufacturing facility of its wholly owned subsidiary, Apitoria P...
Brokerage Report: CLSA expects India pharma market to grow at 8-9% in 2025, Dr. Reddy’s downgraded to ‘Underperform’, Aurobindo Pharma upgraded to ‘Outperform’
CLSA has provided an optimistic outlook on the Indian pharmaceutical market, forecasting an 8-9% growth in 2025, which is slightly better than the US market. The brokerage emphasized that Indian expor...
Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84%
The pharmaceutical sector exhibited a mix of gains and losses in early trading. Here’s a detailed overview: Gainers: Glenmark Pharmaceuticals surged +1.57%, trading at ₹1,527.20. GlaxoSmithKline (Glax...
Pharma sector stocks: Biocon (+3.10%), Aurobindo Pharma (+0.48%), Divis Labs (+0.39%) rise; Mankind Pharma (-1.43%) leads losers
Pharma sector stocks witnessed mixed movement in early trade today, with selective buying in mid-cap stocks while large-cap players faced profit booking. Stock Performance (as of 10:28 AM): Biocon: ₹3...
Pharma stocks: Dr. Reddy’s up 1.70%, Biocon down 2.17%, Lupin falls 2.18%
As of 10:58 AM, pharma stocks exhibited mixed performance. Here are the key highlights: Gainers: Dr. Reddy’s Laboratories: Leading the gains with a 1.70% rise, trading at ₹1,374.55. Cipla: Slight upti...
Pharma sector stocks performance: Ipca Labs gains 1.23%, Biocon up 0.84%, Sun Pharma and Torrent Pharma slip over 1%
Pharma sector stocks displayed a mixed trend as of 10:33 AM. Ipca Labs led the gainers with a 1.23% rise, followed by Biocon at 0.84% and Dr. Reddy’s at 0.65%. On the downside, Sun Pharma (-1.15%), Au...
Aurobindo Pharma (+1.58%), Mankind Pharma (+1.48%), Zydus Lifesciences (+0.91%) lead pharma stock gains
As of 10:00 AM, pharma stocks are trading mixed, with Aurobindo Pharma, Mankind Pharma, and Zydus Lifesciences emerging as top gainers. Meanwhile, Biocon (-0.72%), Ipca Labs (-0.40%), and Dr. Reddy’s ...
Aurobindo Pharma subsidiary gets approval for oncology biosimilar Bevqolva from UK’s MHRA
Aurobindo Pharma Limited has recently informed exchanges that its subsidiary, CuraTeQ Biologics received approval for its bevacizumab biosimilar, Bevqolva, from the UK’s Medicines and Healthcare produ...
Aurobindo Pharma subsidiary completes US FDA inspection at API Unit V with two minor observations
Aurobindo Pharma Limited has announced the successful completion of a US Food and Drug Administration (US FDA) inspection at Unit V of its wholly-owned subsidiary, Apitoria Pharma Private Limited. The...
Aurobindo Pharma arm CuraTeQ gets positive EMA opinion for biosimilar Zefylti
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefyl...
Aurobindo Pharma shares rise after CuraTeQ’s biosimilar Zefylti gets positive EMA opinion
Shares of Aurobindo Pharma Ltd surged 1.34% on Friday as the company’s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, received a positive opinion for its biosimilar Zefylti from the European ...
Stocks to watch, December 16: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, and Aurobindo Pharma and more in focus today
Here are our stocks to watch today on Dec 16, 2024: Biocon, Lupin, Bharat Forge, Radico Khaitan, Dixon Tech, Aurobindo Pharma, PVR Inox, RITES, Godrej Agrovet, HBL Power, Borosil Renewables, JK Paper ...
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Lookout notice out for Jagan's MP, Aurobindo Pharma official
Andhra Pradesh CID has issued a lookout notice against YSRCP MP Vijayasai Reddy, his son-in-law, and another individual, preventing them from leaving the country. They are accused of extorting shares ...
Aurobindo Pharma arm Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and m...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Aurobindo Pharma shares surge 2% after on strategic collaboration with global pharma major
Aurobindo Pharma shares rose over 2% following its announcement of a collaboration and license agreement with a global pharma major. The partnership focuses on developing and commercializing products ...
Aurobindo Pharma subsidiary signs strategic collaboration for respiratory products with global pharma
Aurobindo Pharma USA Inc., a fully owned subsidiary of Aurobindo Pharma Limited, has entered into a Collaboration and License Agreement with a leading global pharmaceutical company on November 22, 202...
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Q2 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure
In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...